Additional Listing of Shares

RNS Number : 8702R

Genedrive PLC

19 June 2018

 

For release: 19 June 2018

genedrive plc ("genedrive" or the "Company")

Additional Listing of Shares

Genedrive plc announces that it has issued 93,669 ordinary 1.5p shares in the capital of the Company ("Ordinary Shares") to settle shares owing under the Epistem Share Incentive Plan. 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 25 June 2018. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

Following admission, the Company's issued share capital will comprise 18,783,115 Ordinary Shares and each Ordinary Share carries one vote.  There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 18,873,115. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

-  Ends  -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              [phone]

Matthew Fowler: CFO

Peel Hunt LLP

James Steel                                                                                                                       [phone]

Oliver Jackson

Consilium Strategic Communications

Chris Gardner                                                                                                                    [phone]

Matthew Neal

Laura Thornton

[e-mail] 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA  and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com

 

END

 

 

ALSUKARRWNANAAR